Related references
Note: Only part of the references are listed.Production of 177Lu for Targeted Radionuclide Therapy: Available Options
Ashutosh Dash et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
How to calculate sample size in animal studies?
Jaykaran Charan et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2013)
Assessing Antibody Pharmacokinetics in Mice with In Vivo Imaging
Jack Hoppin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Shripad V. Bhagwat et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Mohammad Tabrizi et al.
AAPS JOURNAL (2010)
Mitochondrial F1Fo-ATP synthase translocates to cell surface in hepatocytes and has high activity in tumor-like acidic and hypoxic environment
Zhan Ma et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2010)
Toxicity and Efficacy of Combined Radioimmunotherapy and Bevacizumab in a Mouse Model of Medullary Thyroid Carcinoma
Pierre-Yves Salaun et al.
CANCER (2010)
Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using 124I-IMP-R4-Labeled Antibody ch806
Fook T. Lee et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Dual functions of a monoclonal antibody against cell surface F1F0 ATP synthase on both HUVEC and tumor cells
Xia Zhang et al.
ACTA PHARMACOLOGICA SINICA (2008)
A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies
Lin Li et al.
BIOCONJUGATE CHEMISTRY (2008)
Effect of a novel inhibitory mAb against β-subunit of F1F0 ATPase on HCC
Jingbo Wang et al.
CANCER BIOLOGY & THERAPY (2008)
Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody
Thamar H. Stollman et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Direct targeting of tumor cell F1F0 ATP-synthase by radioiodine angiostatin in vitro and in vivo
Kyung-Ho Jung et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Anglostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase
Sulene L. Chi et al.
CANCER RESEARCH (2007)
Optimization of Radioimmunotherapy of solid tumors: Biological impediments and their modulation
Maneesh Jain et al.
CLINICAL CANCER RESEARCH (2007)
Ectopic localization of mitochondrial ATP synthase: A target for anti-angiogenesis intervention?
DJ Kenan et al.
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES (2005)
Distribution and pharmacokinetic analysis of angiostatin radioiodine labeled with high stability
SH Song et al.
NUCLEAR MEDICINE AND BIOLOGY (2005)
Angiostatin's molecular mechanism: Aspects of specificity and regulation elucidated
ML Wahl et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
In vivo evaluation of 177Lu- and 67/64Cu-labelled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors
J Grünberg et al.
CLINICAL CANCER RESEARCH (2005)
Specific endothelial binding and tumor uptake of radiolabeled angiostatin
KH Lee et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis
LO Martinez et al.
NATURE (2003)
Pharmacokinetics and biodistribution of genetically engineered antibodies
SK Batra et al.
CURRENT OPINION IN BIOTECHNOLOGY (2002)
Role of angiogenesis in tumor growth and metastasis
J Folkman
SEMINARS IN ONCOLOGY (2002)
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer
RS Herbst et al.
SEMINARS IN ONCOLOGY (2002)
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Endothelial cell surface F1-Fo ATP synthase is active in ATP synthesis and is inhibited by angiostatin
TL Moser et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49
SVS Kashmiri et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and T84.66 minibody: Comparison to radioiodinated fragments
PJ Yazaki et al.
BIOCONJUGATE CHEMISTRY (2001)
Share Paper
